Kizzmekia S Corbett

List of Publications by Year in Descending Order

54 papers	12,535 citations	29 h-index	56 g-index
56 ext. papers	17,277 ext. citations	25.2 avg, IF	7.11 L-index

#	Paper	IF	Citations
54	Vaccine-elicited murine antibody WS6 neutralizes diverse beta-coronaviruses by recognizing a helical stem supersite of vulnerability. **2022**,		1
53	mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits similar B cell expansion, neutralizing responses, and protection from Omicron.. *Cell*, **2022**,	56.2	22
52	LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants.. *Cell Reports*, **2022**, 39, 110812	10.6	23
51	Variant SARS-CoV-2 mRNA vaccines confer broad neutralization as primary or booster series in mice. *Vaccine*, **2021**,	4.1	23
50	Career advice from my father: "Go where you are loved". *Molecular Biology of the Cell*, **2021**, 32, ae3	3.5	
49	Protection from SARS-CoV-2 Delta one year after mRNA-1273 vaccination in rhesus macaques coincides with anamnestic antibody response in the lung.. *Cell*, **2021**,	56.2	24
48	Protection against SARS-CoV-2 Beta variant in mRNA-1273 vaccine-boosted nonhuman primates. *Science*, **2021**, 374, 1343-1353	33.3	32
47	Stabilized coronavirus spike stem elicits a broadly protective antibody. *Cell Reports*, **2021**, 37, 109929	10.6	18
46	Protection from SARS-CoV-2 Delta one year after mRNA-1273 vaccination in nonhuman primates is coincident with an anamnestic antibody response in the lower airway **2021**,		4
45	Serologic Cross-Reactivity of SARS-CoV-2 with Endemic and Seasonal Betacoronaviruses. *Journal of Clinical Immunology*, **2021**, 41, 906-913	5.7	68
44	Vaccination with SARS-CoV-2 Spike Protein and AS03 Adjuvant Induces Rapid Anamnestic Antibodies in the Lung and Protects Against Virus Challenge in Nonhuman Primates **2021**,		13
43	The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates. *Science Translational Medicine*, **2021**, 13,	17.5	169
42	Immune Correlates of Protection by mRNA-1273 Immunization against SARS-CoV-2 Infection in Nonhuman Primates **2021**,		24
41	Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine. *New England Journal of Medicine*, **2021**, 384, 1468-1470	59.2	284
40	LY-CoV1404 potently neutralizes SARS-CoV-2 variants **2021**,		31
39	SARS-CoV-2 Vaccines Elicit Durable Immune Responses in Infant Rhesus Macaques **2021**,		1
38	Variant SARS-CoV-2 mRNA vaccines confer broad neutralization as primary or booster series in mice **2021**,		34

37	Evaluation of mRNA-1273 against SARS-CoV-2 B.1.351 Infection in Nonhuman Primates **2021**,		2
36	Durability of mRNA-1273-induced antibodies against SARS-CoV-2 variants **2021**,		21
35	SARS-CoV-2 vaccines elicit durable immune responses in infant rhesus macaques. *Science Immunology*, **2021**, 6,	28	12
34	Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants. *Science*, **2021**, 373,	33.3	80
33	Newcastle Disease Virus-Like Particles Displaying Prefusion-Stabilized SARS-CoV-2 Spikes Elicit Potent Neutralizing Responses. *Vaccines*, **2021**, 9,	5.3	13
32	Antibodies with potent and broad neutralizing activity against antigenically diverse and highly transmissible SARS-CoV-2 variants **2021**,		13
31	Protective antibodies elicited by SARS-CoV-2 spike protein vaccination are boosted in the lung after challenge in nonhuman primates. *Science Translational Medicine*, **2021**, 13,	17.5	17
30	COVID-19 vaccine mRNA-1273 elicits a protective immune profile in mice that is not associated with vaccine-enhanced disease upon SARS-CoV-2 challenge. *Immunity*, **2021**, 54, 1869-1882.e6	32.3	16
29	Protection against SARS-CoV-2 Beta Variant in mRNA-1273 Boosted Nonhuman Primates **2021**,		8
28	mRNA-1273 protects against SARS-CoV-2 beta infection in nonhuman primates. *Nature Immunology* , **2021**, 22, 1306-1315	19.1	32
27	Durability of mRNA-1273 vaccine-induced antibodies against SARS-CoV-2 variants. *Science*, **2021**, 373, 1372-1377	33.3	150
26	Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates. *Science*, **2021**, 373, eabj0299	33.3	86
25	mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants **2021**,		219
24	Structural Basis for Potent Neutralization of Betacoronaviruses by Single-Domain Camelid Antibodies. *Cell*, **2020**, 181, 1004-1015.e15	56.2	319
23	Glycan repositioning of influenza hemagglutinin stem facilitates the elicitation of protective cross-group antibody responses. *Nature Communications*, **2020**, 11, 791	17.4	21
22	Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. *Science*, **2020**, 367, 1260-1263	33.3	5176
21	Prototype pathogen approach for pandemic preparedness: world on fire. *Journal of Clinical Investigation*, **2020**, 130, 3348-3349	15.9	17
20	Structure-Based Design with Tag-Based Purification and In-Process Biotinylation Enable Streamlined Development of SARS-CoV-2 Spike Molecular Probes. *SSRN Electronic Journal*, **2020**, 3639618	1	3

19	Validation of a SARS-CoV-2 spike protein ELISA for use in contact investigations and serosurveillance **2020**,		39
18	SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen Preparedness **2020**,		62
17	A Platform Incorporating Trimeric Antigens into Self-Assembling Nanoparticles Reveals SARS-CoV-2-Spike Nanoparticles to Elicit Substantially Higher Neutralizing Responses than Spike Alone **2020**,		2
16	Structure-Based Design with Tag-Based Purification and In-Process Biotinylation Enable Streamlined Development of SARS-CoV-2 Spike Molecular Probes **2020**,		4
15	Serologic cross-reactivity of SARS-CoV-2 with endemic and seasonal Betacoronaviruses **2020**,		43
14	LY-CoV555, a rapidly isolated potent neutralizing antibody, provides protection in a non-human primate model of SARS-CoV-2 infection **2020**,		64
13	Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults. *New England Journal of Medicine*, **2020**, 383, 2427-2438	59.2	737
12	SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. *Nature*, **2020**, 586, 567-571	50.4	594
11	Structure-Based Design with Tag-Based Purification and In-Process Biotinylation Enable Streamlined Development of SARS-CoV-2 Spike Molecular Probes. *Cell Reports*, **2020**, 33, 108322	10.6	35
10	An mRNA Vaccine against SARS-CoV-2 - Preliminary Report. *New England Journal of Medicine*, **2020**, 383, 1920-1931	59.2	1704
9	Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates. *New England Journal of Medicine*, **2020**, 383, 1544-1555	59.2	612
8	A platform incorporating trimeric antigens into self-assembling nanoparticles reveals SARS-CoV-2-spike nanoparticles to elicit substantially higher neutralizing responses than spike alone. *Scientific Reports*, **2020**, 10, 18149	4.9	41
7	Design of Nanoparticulate Group 2 Influenza Virus Hemagglutinin Stem Antigens That Activate Unmutated Ancestor B Cell Receptors of Broadly Neutralizing Antibody Lineages. *MBio*, **2019**, 10,	7.8	50
6	Importance of Neutralizing Monoclonal Antibodies Targeting Multiple Antigenic Sites on the Middle East Respiratory Syndrome Coronavirus Spike Glycoprotein To Avoid Neutralization Escape. *Journal of Virology*, **2018**, 92,	6.6	119
5	Stabilized coronavirus spikes are resistant to conformational changes induced by receptor recognition or proteolysis. *Scientific Reports*, **2018**, 8, 15701	4.9	259
4	Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen. *Proceedings of the National Academy of Sciences of the United States of America*, **2017**, 114, E7348-E7357	11.5	615
3	Pre-fusion structure of a human coronavirus spike protein. *Nature*, **2016**, 531, 118-21	50.4	474
2	mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits comparable B cell expansion, neutralizing antibodies and protection against Omicron		12

List of Publications

1 Structural Basis for Potent Neutralization of Betacoronaviruses by Single-domain Camelid Antibodies 10